gene therapy

Gene therapy for SCID-X1

A new gene therapy study in New England Journal of Medicine reports positively on the use of a self-inactivated  lentivirus supplemented by an insulator and a codon-optimised human common γ chain gene to treat SCID-X1 disease.

A new gene therapy study in New England Journal of Medicine reports positively on the use of a self-inactivated  lentivirus supplemented by an insulator and a codon-optimised human common γ chain gene to treat SCID-X1 disease.
May 20, 2019

A new gene therapy study in New England Journal of Medicine reports positively on the use of a self-inactivated  lentivirus (i.e. a lentivirus deleted of long terminal repeat (LTR) sequences containing potential viral transcriptional elements) supplemented by an insulator and a codon-optimised human common γ chain (γc) gene (also known as IL2RG or Interleukin 2 receptor subunit gamma) to treat X-linked severe combined immunodeficiency (SCID-X1) or “bubble boy” disease.

After around 16 months of follow-up, results from eight treated patients show reconstitution of functional T cells and B cells, and normalization of NK-cell counts.

Vector site integration data generally showed polyclonal pattern, but long term follow-up will be needed to show absence of vector-induced leukaemia to complement the promising data.

Search News & Events

  • Filter by category

Share

Related news and events

Christmas season greatings

Season’s Greetings

We wish you Happy ‘Xmas, Prosperous New Year and Health for you and your loved ones.

For further information

If you are interested in our services, or wish to get in touch for a general enquiry, please contact us for more information.

Fill the form and we will contact you as soon as possible.

You can also follow us on:

Schedule a Free Meeting

Schedule here a free 30-minutes meeting with one of our consultants and tell us about your project, challenges or doubts. 

We will be happy to assist you!

Schedule a meeting